Caricamento...
PCSK9 inhibitors: A new era of lipid lowering therapy
Hyperlipidemia is a well-established risk factor for developing cardiovascular disease (CVD). The recent American College of Cardiology and American Heart Association guidelines on lipid management emphasize treatment of individuals at increased risk for developing CVD events with 3-hydroxy-3-methyl...
Salvato in:
| Pubblicato in: | World J Cardiol |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Baishideng Publishing Group Inc
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5329749/ https://ncbi.nlm.nih.gov/pubmed/28289523 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4330/wjc.v9.i2.76 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|